- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.08. | Sight Sciences Announces FDA Label Expansion For TearCare Dry Eye Therapy | 1 | RTTNews | ||
| 19.08. | Sight Sciences, Inc.: TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease | 428 | GlobeNewswire (Europe) | MENLO PARK, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative interventional technologies... ► Artikel lesen | |
| 10.08. | Sight Sciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.08. | Sight Sciences outlines 2026 revenue of $88M-$92M while lowering adjusted operating expense outlook to $92M-$94M | 2 | Seeking Alpha | ||
| 06.08. | Sight Sciences GAAP EPS of -$0.08 beats by $0.06, revenue of $23.4M beats by $1.71M | 1 | Seeking Alpha | ||
| 05.08. | Earnings Call: Sight Sciences hebt Ausblick für 2026 an, Aktie fällt trotz Q2-Wachstum | - | Investing.com Deutsch | ||
| 05.08. | Sight Sciences: Aetna erweitert Kostenerstattung für Glaukom-Systeme | 7 | Investing.com Deutsch | ||
| SIGHT SCIENCES Aktie jetzt für 0€ handeln | |||||
| 05.08. | Sight Sciences wins FDA clearance for Omni Surgical System | 2 | MassDevice | ||
| 05.08. | FDA clears Sight Sciences' OMNI Ultra glaucoma device | 1 | Investing.com | ||
| 04.08. | Sight Sciences, Inc.: Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System | 144 | GlobeNewswire (Europe) | MENLO PARK, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative interventional technologies... ► Artikel lesen | |
| 22.07. | Sight Sciences, Inc.: Sight Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026 | 1 | GlobeNewswire (USA) | ||
| 05.06. | Sight Sciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.05. | Sight Sciences signals $83M-$89M 2026 revenue outlook while targeting $6M-$8M dry eye sales | 1 | Seeking Alpha | ||
| 06.05. | Sight Sciences, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 23.04. | Sight Sciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.04. | Sight Sciences, Inc.: Sight Sciences Announces the Release of its Sustainability Report | 3 | GlobeNewswire (USA) | ||
| 21.04. | Sight Sciences, Inc.: Sight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026 | 2 | GlobeNewswire (USA) | ||
| 01.04. | Sight Sciences, Inc.: Sight Sciences' Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 30.03. | Sight Sciences secures $34M patent infringement win against Alcon | 3 | MassDevice | ||
| 30.03. | Sight Sciences wins $34M in Alcon patent case, ongoing royalty | 5 | Investing.com |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 5,480 | 0,00 % | Teladoc Health, Inc.: Teladoc Health Appoints Financial Executive Mark Anquillare to Its Board of Directors | NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced the appointment of Mark V. Anquillare to its board of directors. Mr. Anquillare... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,069 | +7,12 % | Dr. Steven S. Sangha: Steven Sangha Announces Voting and Support Agreement for Sernova Biotherapeutics Inc.'s Proposed Business Combination with Seraxis Holdings, Inc. | Toronto, Ontario--(Newsfile Corp. - September 11, 2026) - Steven Sangha announces he has entered into a voting and support agreement ("Voting Agreement") with Seraxis Holdings, Inc. ("Seraxis") in connection... ► Artikel lesen | |
| CERENOME | 1,750 | +0,34 % | Cerenome, Inc.: Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division | HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), today announces the appointment of Samantha... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 2,060 | +5,10 % | ATOSSA THERAPEUTICS, INC. - 8-K, Current Report | ||
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals: Historischer Wendepunkt - darum fliegt die Aktie! | Volltreffer: Bereits im Frühjahr hatte ich die positive Entwicklung bei Sonoma Pharmaceuticals antizipiert und die Nano-Cap-Aktie als hochinteressante Turnaround-Spekulation vorgestellt. Damals hatte... ► Artikel lesen | |
| TANDEM DIABETES | 14,900 | +1,36 % | Tandem Diabetes Care, Inc.: Tandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility with Abbott FreeStyle Libre 3 Plus Sensor in Five International Markets | Compatibility now available in five countries, with additional markets expected throughout 2026.Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company... ► Artikel lesen | |
| CO-DIAGNOSTICS | 1,020 | +5,15 % | Co-Diagnostics, Inc. - 8-K, Current Report | ||
| QUIDELORTHO | 9,076 | -1,99 % | QuidelOrtho Corporation: QuidelOrtho Reports Second Quarter 2026 Financial Results | ? Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth ?
? Excluding China, total revenue grew 6% both as... ► Artikel lesen | |
| VERU | 2,480 | +3,55 % | Veru Inc.: Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress | -- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients - -- Phase 2b PLATEAU clinical trial interim analysis and... ► Artikel lesen | |
| LIFEWARD | 7,160 | +1,85 % | Lifeward legt Termin für jährliche und außerordentliche Hauptversammlung 2026 fest | ||
| CLOVER HEALTH INVESTMENTS | 3,920 | +1,03 % | Clover Health Investments, Corp.: Clover Health Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for Full Fiscal Year 2026 | WILMINGTON, Del., April 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) ("Clover" or the "Company"), a physician enablement company committed to bringing access to great... ► Artikel lesen | |
| SENSEONICS | 7,850 | -5,99 % | Senseonics sees activist investor take a major stake | ||
| TEMPEST THERAPEUTICS | 0,806 | -16,44 % | Tempest Therapeutics: Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform | -Transaction complements Tempest's existing CD7-targeted lipid nanoparticle in vivo CAR-T delivery platform, which is planned to enter the clinic later this year -Lead BCMA/GPRC5D dual-targeting in... ► Artikel lesen | |
| NANO-X IMAGING | 0,728 | -2,39 % | Nano-X Imaging Ltd. - 6-K, Report of foreign issuer | ||
| IMUNON | 1,220 | 0,00 % | Imunon, Inc.: IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer | Enrollment momentum exceeding expectations is based on highly promising survival (OS) data and well tolerated safety profile demonstrated in the Company's large, randomized Phase II study, OVATION... ► Artikel lesen |
Das Unternehmen SIGHT SCIENCES INC kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,11 % bei einem Aktienkurs von 8,220 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SIGHT SCIENCES INC finden Sie auf Wallstreet Online.